1. Cancer Biology
Download icon

Biomarkers: Improving survival prediction for melanoma

  1. Mykyta Artomov  Is a corresponding author
  1. Massachusetts General Hospital, United States
  2. Broad Institute, United States
Insight
Cite this article as: eLife 2019;8:e48145 doi: 10.7554/eLife.48145
1 figure

Figures

Different ways to predict survival rates for patients with melanoma.

Some patients with a given cancer have higher survival rates than other patients with the same type of cancer: the discovery of signatures for higher (green line in graph) or lower (red line) survival rates would help doctors to manage the expectations of their patients. Survival predictions for cutaneous melanoma were originally based on clinical parameters: tumor location, Breslow thickness (how deep it spreads into the skin), stage (size and distance spread), and grade (how its cells look under the microscope). Advances in cancer genetics led to the discovery of biomarkers (such as the V600E mutation in the BRAF gene) that enabled more accurate predictions. Advances in transcriptomics also led to biomarkers, such as the level of transcription of a gene called MITF. Guo et al. complemented these approaches by analyzing epigenomics data to identify a biomarker based on DNA methylation marks (orange box): the predictive power of the new biomarkers is higher than that of previous biomarkers.

IMAGE CREDIT:Rw251 [CC0 1.0].

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Download citations (links to download the citations from this article in formats compatible with various reference manager tools)

Open citations (links to open the citations from this article in various online reference manager services)